Background Although human epidermal growth factor receptor 2 (ERBB2/HER2) is a validated therapeutic target, the significance of ERBB3 (HER3) alterations across solid tumours remains poorly defined. We characterised such alterations to clarify the genomic landscape relevant to HER3-directed strategies, distinguishing s...
M. Kwon, Y. Go, J. Shin et al.· ESMO Open· 0 citations
Biliary tract cancers (BTCs) are associated with poor outcomes despite recent incorporation of immune checkpoint inhibitors into first-line chemotherapy. Human epidermal growth factor receptor 2 (HER2) overexpression or amplification defines a therapeutically targetable subset of BTC but its integration into first-line...
Choong-kun Lee, Taek Chung, I. Kim et al.· Nature Medicine· 0 citations
Simple Summary Melanoma is a serious skin cancer, and in East Asian patients it frequently arises at acral sites or on internal mucosal surfaces rather than on sun-exposed skin. These forms tend to respond less well to immunotherapy, the current standard first-line treatment, yet it remains unclear which tumors benefit...
Seo Yoon Jang, Minsuk Kwon, Jeeyun Lee et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.